GlassScriptPhysician profile
Deven Riley
NPI 1487329728
$3,668.04
in general payments reported to CMS, 2019-2025
22 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,024 · 2023: $1,060 · 2024: $545 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.38 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $482.65 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Indivior INC. | $454.11 | 2022-2025 | Sublocade |
| Braeburn INC. | $416.27 | 2023-2025 | Brixadi |
| Alkermes, INC. | $328.72 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $286.98 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $150.94 | 2024-2025 | Veozah |
| Tris Pharma INC | $150.17 | 2024-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $125.04 | 2023-2024 | Auvelity |
| Corcept Therapeutics | $109.24 | 2024 | Korlym |
| Exact Sciences Corporation | $94.49 | 2025 | Cologuard Collection Kit |
| Uswm, LLC | $91.43 | 2022-2023 | Lucemyra, Zimhi |
| Hikma Pharmaceuticals USA | $84.00 | 2022 | |
| Intra-Sana Laboratories | $80.09 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Gilead Sciences, INC. | $69.24 | 2023 | Epclusa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $38.32 | 2023-2025 | Uzedy |
| Novo Nordisk INC | $34.67 | 2024 | Wegovy |
| Lilly USA, LLC | $28.72 | 2025 | Zepbound, Mounjaro |
| Biogen, INC. | $22.56 | 2025 | Zurzuvae |
| Orexo US, INC. | $15.96 | 2023 | Zubsolv |
| Vanda Pharmaceuticals INC. | $15.06 | 2025 | Fanapt |
| Noven Therapeutics, LLC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deven Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.